Affiliation:
1. School of Nursing and Health Studies, Hong Kong Metropolitan University Hong Kong China
2. School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong Hong Kong China
3. City University of New York Graduate School of Public Health and Health Policy New York NY
Abstract
Background
Establishing the sex‐specific efficacy of cardiovascular medications is pivotal to evidence‐based clinical practice, potentially closing the gender gap in longevity. Trials large enough to establish sex differences are unavailable. This study evaluated sex‐specific effects of commonly prescribed cardiovascular medications on lifespan.
Methods and Results
In a two‐sample Mendelian randomization study, established genetic variants mimicking effects of lipid‐lowering drugs, antihypertensives, and diabetes drugs were applied to genetic associations with lifespan proxied by UK Biobank maternal (n=412 937) and paternal (n=415 311) attained age. Estimates were obtained using inverse variance weighting, with sensitivity analyses where possible. For lipid‐lowering drugs, genetically mimicked PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors were associated with longer lifespan, particularly in men (2.39 years per SD low‐density lipoprotein cholesterol reduction [95% CI, 0.42–4.36],
P
for interaction=0.14). Genetically mimicked treatments targeting
APOC3
,
LPL
, or possibly
LDLR
were associated with longer lifespan in both sexes. For antihypertensives, genetically mimicked β‐blockers and calcium channel blockers were associated with longer lifespan, particularly in men (
P
for interaction=0.17 for β‐blockers and 0.31 for calcium channel blockers). For diabetes drugs, genetically mimicked metformin was associated with longer lifespan in both sexes. No associations were found for genetically mimicked statins, ezetimibe, or angiotensin‐converting enzyme inhibitors.
Conclusions
PCSK9 inhibitors, β‐blockers, and calcium channel blockers may prolong lifespan in the general population, particularly men. Treatments targeting
APOC3
,
LPL
, or
LDLR
and metformin may be relevant to both sexes. Whether other null findings are attributable to lack of efficacy requires investigation. Further investigation of repurposing should be conducted.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Cardiology and Cardiovascular Medicine
Reference66 articles.
1. United Nations Economic Commission for Europe (UNECE) . Gender equality in ageing societies ‐ UNECE Policy Brief on Ageing No. 23. 2020. Accessed 01 Jan 2022. https://unece.org/fileadmin/DAM/pau/age/Policy_briefs/ECE_WG‐1_34.pdf
2. WHO report shows that women outlive men worldwide
3. Variations between women and men in risk factors, treatments, cardiovascular disease incidence, and death in 27 high-income, middle-income, and low-income countries (PURE): a prospective cohort study
4. Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015
5. NIH Inclusion Policies. NIH Office of Research on Women's Health. 2020. Accessed August 18 2020. https://orwh.od.nih.gov/womens‐health/clinical‐research‐trials/nih‐inclusion‐policies
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献